survival analysis demonstrates that patients with the men-1 syndrome had a significantly better survival from diagnosis than patients with sporadic endocrine pancreatic tumors ( median 15.1 years and 5.8 years respectively , p = 0.0068 ) .
C0025267
men-1 syndrome
C0242363
endocrine pancreatic tumors